Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
Harvard Business School

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,859,257

« Back to Dashboard

Title: Isoxazole compounds as cyclooxygenase inhibitors
Abstract:A class of substituted isoxazolyl compounds is described for use in treating cyclooxygenase-2 related disorders. Compounds of particular interest are defined by Formula I ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3, are described in the specification.
Inventor(s): Talley; John J (Brentwood, MO)
Assignee: G. D. Searle & Co. (Skokie, IL)
Filing Date:Aug 14, 1996
Application Number:08/702,417
Claims:1. A method of preparing compounds of Formula II ##STR95## wherein R.sup.4 is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower alkoxycarbonylalkyl, lower aralkyl, methoxy, ethoxy, butoxy, lower alkylthio, lower alkoxyalkyl, lower aryloxyalkyl, lower arylthioalkyl, lower haloalkyl, lower hydroxylalkyl, lower aralkoxyalkyl, lower aryl(hydroxylalkyl), lower carboxyalkoxyalkyl, lower carboxyaryloxyalkyl, lower alkoxycarbonylaryloxyalkyl, lower cycloalkyl and lower cycloalkylalkyl; wherein R.sup.5 is amino; and wherein R.sup.6 is phenyl; wherein R.sup.6 is optionally substituted at a substitutable position with one or more radicals independently selected from lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, amino, lower haloalkoxy, lower alkylamino, phenylamino, lower aminoalkyl, nitro, halo, lower alkoxy, methylenedioxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof, the method comprising the steps of forming a diphenylethanone derivative oxime by treatment of a diphenylethanone derivative with hydroxylamine, treating said oxime with base and an acylating agent to form a diphenylisoxazoline derivative, and forming the (isoxazol-4-yl)benzenesulfonamide by treatment of the isoxazoline with chlorosulfonic acid and ammonia.

2. The method of claim 1 wherein R.sup.4 is selected from hydroxyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, isopentyl, neopentyl, hexyl, chloro, carboxyl, carboxypropyl, carboxymethyl, carboxyethyl, carboxybutyl, carboxypentyl, methoxycarbonylmethyl, methoxycarbonylethyl, methoxycarbonylpropyl, methoxy, ethoxy, butoxy, methoxymethyl, phenoxymethyl, 4-fluorophenoxymethyl, pyridinylthiomethyl, methylthio, ethylthio, butylthio, ethylsulfinyl, butylsulfinyl, phenylsulfinyl, methoxyethyloxymethyl, benzyloxymethyl, phenylethoxymethyl, fluoromethyl, difluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxylmethyl, hydroxylpropyl, hydroxylethyl, 2-hydroxy-2-methylpentyl, cyclohexyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclohexylmethyl, cyclohexylethyl, cyclobutylethyl, cyclopentylmethyl, cycloheptylpropyl, and lower aralkyl selected from benzyl and phenylethyl, wherein the phenyl ring is optionally substituted at a substitutable position with fluoro, chloro, bromo, iodo, methyl, and methoxy; and wherein R.sup.6 is phenyl; wherein R.sup.6 is optionally substituted at a substitutable position with one or more radicals independently selected from trifluoromethoxy, methylsulfinyl, ethylsulfinyl, methyl, ethyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, cyano, carboxyl, methoxycarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, fluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, hydroxymethyl, fluoro, chloro, bromo, iodo, methoxy, ethoxy, propoxy, n-butoxy, pentoxy, hexyloxy, methylenedioxy, methylthio, ethylthio, butylthio, and hexylthio; or a pharmaceutically-acceptable salt thereof.

3. The method of claim 2 wherein the compound is selected from compounds, or a pharmaceutically acceptable salt thereof, of the group consisting of




















[4-[4-(aminosulfonyl)phenyl]-3-phenylisoxazol-5-yl]carboxylic acid;





[4-[4-(aminosulfonyl)phenyl]-3-phenyl-isoxazol-5-yl]acetic acid;

[4-[4-(aminosulfonyl)phenyl]-3-phenyl-isoxazol-5-yl]propanoic acid;

ethyl [4-[4-(aminosulfonyl)phenyl]-3-phenyl-isoxazol-5-yl]propanoate; and

[4-[4-(aminosulfonyl)phenyl]-3-(3-fluoro-4-methoxyphenyl)isoxazol-5-yl]prop anoic acid.

4. The method of claim 2 wherein the compound is 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide.

5. The method of claim 1 wherein the acylating agent is selected from anhydrides, acyl imidazoles and esters.

6. The method of claim 5 wherein the acylating agent is methyl acetate.

7. The method of claim 1 wherein the base is lithium diisopropylamide or butyllithium.

8. The method of claim 1 wherein the ammonia is concentrated ammonium hydroxide.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.